- Trial phase
- Approved
- Time to market
- Already approved and marketed (FDA approval July 20, 2023).
- Why 4/10
- CYFENDUS was FDA-approved in July 2023 and is already commercialized with no pending PDUFA, pivotal readout, or other hard binary catalyst scheduled in the next ~12 months. The drug's revenue is driven by periodic U.S. government contract modifications, which are not dated binary events. As an approved product without a pending regulatory decision, the impact score defaults to the 3-5 range.
CYFENDUS is already approved and generating government contract revenue; watch for future BARDA contract modifications and any label expansion (e.g., pediatric or older adult populations) that could open new procurement. The Phase 2 booster study (NCT05997264) is ongoing but not a near-term binary. The stock's next major catalyst is company-wide, not drug-specific: the Q3 2026 earnings just reported today (Nov 2) showed anthrax MCM revenue up $23.7M year-over-year on CYFENDUS timing, but overall revenue fell 52% and guidance was lowered.
Price Chart
Executive Summary
CYFENDUS (AV7909) is Emergent BioSolutions' FDA-approved two-dose anthrax vaccine for post-exposure prophylaxis, approved in July 2023. It offers faster protection than the older three-dose BioThrax vaccine and is sold primarily to the U.S. government for the Strategic National Stockpile under BARDA contracts. The drug is already commercialized with no pending regulatory binary catalyst. In Q3 2026, higher CYFENDUS sales drove a $23.7M year-over-year increase in anthrax medical countermeasure revenue, but the company overall faces headwinds: total revenue fell 52%, gross margins compressed, and full-year guidance was lowered. The stock trades near $5-6 with a mean analyst price target of $11.
How It Works
CYFENDUS is a vaccine that trains the immune system to recognize and neutralize the toxins produced by Bacillus anthracis, the bacterium that causes anthrax. It contains inactivated anthrax proteins plus an adjuvant (a booster ingredient) to strengthen the immune response. Unlike the older three-dose BioThrax vaccine, CYFENDUS requires only two doses, offering faster protection after someone has been exposed to anthrax spores. It is given together with antibiotics as part of post-exposure treatment.
Trial Status
CYFENDUS was approved by the FDA on July 20, 2023, based on a pivotal Phase 3 study evaluating immunogenicity and safety, a Phase 2 non-interference study with antibacterial drugs, and non-clinical efficacy studies. A Phase 2 booster study (NCT05997264) is ongoing to evaluate safety and immune response of different vaccination schedules and booster doses. An observational study (NCT07268612) is evaluating clinical benefit and safety in real-world post-exposure use.
The Two-Sided Case
Upcoming Catalysts
- Future BARDA contract modifications or renewals for CYFENDUS supply to the Strategic National Stockpile
- Phase 2 booster study (NCT05997264) results on 6- and 12-month booster schedules
- Potential label expansion to pediatric or older adult populations
- Observational study (NCT07268612) real-world safety and efficacy data
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Emergent BioSolutions Inc. 8-K EBS ·Originating report